Ibio (0JV0) AI Stock Analysis

1 Followers

Ibio

(Frankfurt:0JV0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low LeverageVery low leverage gives iBio greater financial flexibility than a heavily indebted biotechnology company. The modest debt burden may leave more capacity to fund research, withstand development setbacks, and pursue strategic financing while candidates advance.

Negative Factors

Persistent Large LossesLosses remain exceptionally large relative to the current revenue base, showing that iBio’s research platform has not yet reached an economically self-sustaining scale. Persistent deficits can erode equity and require continuing external funding before products generate meaningful returns.

Ibio (0JV0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 53.00M
Dividend Yield: ―
Average Volume (3M): 500
Price to Earnings (P/E): -3.0
Beta (1Y): 1.70
Revenue Growth: 107.86%
EPS Growth: 73.55%
Country: Germany
Employees: 23
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Ibio Business Overview & Revenue Model

Company Description

iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioproce...

Ibio Risk Analysis

Ibio disclosed 62 risk factors in its most recent earnings report. Ibio reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.Conducting clinical trials in Australia exposes us to additional regulatory, operational and legal risks that could delay development of our product candidates and increase our costs.Q2, 2026

2.Our Phase 1 clinical trial of IBIO-600 is subject to significant risks that could delay or prevent further development of this product candidate.Q2, 2026

3.Delays or difficulty in the enrollment of patients in any or all of our clinical trials could increase our development costs and delay completion of our clinical trials and associated regulatory submissions.Q2, 2026

Ibio Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:0JV0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NERV	54Neutral	$124.09M	-0.10	167.68%	―	―	-1306.84%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PULM	44Neutral	$4.93M	-1.19	-109.26%	―	-100.00%	49.19%
FBLG	40Underperform	$6.15M	-0.17	-536.78%	―	―	22.10%
CMMB	38Underperform	$9.75M	-1.32	-70.81%	―	―	56.99%

* Healthcare Sector Average

Performance Comparison

DE:0JV0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:0JV0	Ibio Inc	0.68	-0.35	-34.47%
NERV	Minerva Neurosciences	2.56	-1.29	-33.51%
PULM	Pulmatrix	1.31	-3.58	-73.21%
CMMB	Chemomab Therapeutics Ltd.	1.35	-1.20	-47.06%
ASBP	Aspire Biopharma Holdings, Inc.	8.80	-117.44	-93.03%
FBLG	FibroBiologics, Inc.	0.99	-5.72	-85.18%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Ibio AI Stock Analysis